Inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease with less severe haemodynamics: a post hoc analysis of the INCREASE study.

The Bayesian analyses confirm a strong trend toward benefit for the use of inhaled treprostinil in both the PVR<4 WU and ≤5 WU subgroups with regard to disease progression, with posterior probabilities of an HR<1 consistently above 75% for both PVR stratifications across all priors apart from the pessimistic prior.

also in 5,725 other papers